Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM4B | O94953 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058857 | 1.00 | CYP3A4 (0.53) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL28939613 | 0.92 | CYP3A4 (0.51) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL23704817 | 0.91 | CYP3A4 (0.51) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL30059003 | 0.90 | CYP3A4 (0.50) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL23705043 | 0.90 | CYP3A4 (0.50) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL23714846 | 0.90 | WNT3A (0.51) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL30058825 | 0.89 | CYP3A4 (0.49) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL23714972 | 0.89 | CYP3A4 (0.49) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL23704778 | 0.89 | MAPT (0.47) | CYP3A4ROCK1PRKACAALDH1A1MAPT | |
| SCHEMBL30058923 | 0.89 | MAPT (0.47) | CYP3A4ROCK1PRKACAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115484948-A | Compound and use thereof | 福宏治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-4096657-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20170022262-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CYP3A4 3718/4885ROCK1 4248/4885PRKACA 755/4885 |
| US-20170022262-A1 | CRYSTALLINE INSULIN-CONJUGATES | IAPP, INSR, GPR119 | CYP3A4 2655/4885ROCK1 3862/4885PRKACA 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.